GEN-27, a Newly Synthetic Isoflavonoid, Inhibits the Proliferation of Colon Cancer Cells in Inflammation Microenvironment by Suppressing NF-κB Pathway

Figure 7

GEN-27 inhibited IL-1β-induced proliferation of human colon cancer cells. HCT116 cells were either left untreated or treated with 30 ng/mL IL-1β, or 30 ng/mL IL-1β and 10 μM GEN-27 together, or combination of 30 ng/mL IL-1β, 10 μM GEN-27, and 20 μM Bay 11-7082 for 24 h. (a and i) Cell viability was assessed using an MTT assay and the results are expressed as the percentage of surviving cells over control cells. (b, d, and e) NF-κB/p65 nuclear translocation and protein levels of total NF-κB/p65, p-IκBα, IκBα, p-IKKα/β, IKKα/β, PCNA, bcl-2, and cyclin D1 were determined by Western blot. (c, g, and h) The quantitation of those proteins expression levels relative to β-actin expression according to (b, d, and e). (f) NF-κB/p65 nuclear translocation and total protein levels of p65 with or without p65 overexpression. (j, k, and l) Protein levels of total NF-κB/p65, PCNA, bcl-2, and cyclin D1 were determined by Western blot. The relative expressions of those proteins were normalized to β-actin. All graphic data shown are the means ± SDs. Results are representative of those obtained from three independent experiments. and compared with control; and versus IL-1β alone.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)